Etoposide-loaded immunoliposomes as active targeting agents for GD2-positive malignancies

Brown, Brandon; Patanam, Tariq; Mobli, Keyan; Celia, Christian; Zage, Peter E.; Bean, Andrew J.; Tasciotti, Ennio

doi:10.4161/cbt.28875

Cited by 37 publications

(18 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because of an evident expression of GD2 on NB cells surface and role in NB pathogenesis and progression, it potentially serves as a target in NB therapy (Saito et al, ; Yang & Sondel, ). GD2 has been utilized as a target in monoclonal antibody therapy and has been the primary target of antibody recognition in NB (Brown, ; Kushner et al, ; Thurin et al, ). Various researches demonstrated that normal tissue in brain only expression GD2 where is inaccessible to circulating antibodies.…”

Section: Introductionmentioning

confidence: 99%

GD2‐targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma

Gholamin

Mirzaei

Razavi

et al. 2017

Journal Cellular Physiology

103

112

View full text Add to dashboard Cite

Neuroblastoma (NB) with various clinical presentation is a known childhood malignancy. Despite significant progress in treatment of NB afflicted patients, high risk disease is usually associated with poor outcome, resulting in long-term survival of less that 50%. Known as a disease most commonly originated form the nerve roots, the variants involved in NB imitation and progression remain to be elucidated. The outcome of low to intermediate risk disease is favorable whereas the high risk NB disease with dismal prognosis, positing the necessity of novel approaches for early detection and prognostication of advanced disease. Tailored immunotherapy approaches have shown significant improvement in high-risk NB patients. It has found a link between Gangliosides and progression of NB. The vast majority of neuroblastoma tumors express elevated levels of GD2, opening new insight into using anti-GD2 drugs as potential treatments for NBs. Implication of anti-GD2 monoclonal antibodies for treatment of high risk NBs triggers further investigation to unearth novel biomarkers as prognostic and response biomarker to guide additional multimodal tailored treatment approaches. A growing body of evidence supports the usefulness of miRNAs to evaluate high risk NBs response to anti-GD2 drugs and further prevent drug-related toxicities in refractory or recurrent NBs. miRNAs and circulating proteins in body fluids (plasma and serum) present as potential biomarkers in early detection of NBs. Here, we summarize various biomarkers involved in diagnosis, prognosis and response to treatment in patients with NB. We further attempted to overview prognostic biomarkers in response to treatment with anti-GD2 drugs.

show abstract

Section: Introductionmentioning

confidence: 99%

GD2‐targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma

Gholamin

Mirzaei

Razavi

et al. 2017

Journal Cellular Physiology

103

112

View full text Add to dashboard Cite

show abstract

“…Moreover, newly developed different liposomal combinations/formulations and liposomal vaccines have shown promising results in clinical studies and in commercial applications. In all, liposomal formulations are still important and potential tool for its clinical application of nanomedicines [45,50,61,63,65,.…”

Section: Discussionmentioning

confidence: 99%

“…Disialo-ganglioside GD-2 is a tumor marker expressed in many cancers and targeting cancer cells by antibodies against GD2 is a major strategy employed in cancer therapy [44]. Immuno-liposomes coated with anti-GD2 antibody, encapsulating anticancer drug etoposide targeting GD2 expressing cancer cells, has been reported to enter targeted cells via clathrin-coated pits, thereby causing reduction in cell proliferation in in-vitro studies and offers advantage over conventional chemotherapeutics in specific cancer cell targeting [45].…”

Section: Cancer Targetingmentioning

confidence: 99%

Multidynamic Liposomes in Nanomedicine: Technology, Biology, Applications, and Disease Targeting

Ghosh

Ansar²

2014

Nanoparticles' Promises and Risks

View full text Add to dashboard Cite

Biocompatible and biodegradable liposome nanomedicine are finding large-scale application in delivery of drugs, RNA, antisense oligonucleotides, DNA, plasmids carrying gene, antioxidants to targeted sites for diagnosis, and treatment at cellular and molecular level of disease both in human and livestock.Conventional drug delivery system suffers from the disadvantage of narrow therapeutic index, poor serum solubility, and nonspecific target effects. Circumventing this problem, liposome drug nanoparticles are designed with the advantage of enhanced permeability, retention effect, selective targeted delivery, stimuli-induced release that can evade the host defense system, cross the bloodbrain barrier, thus conferring, synergetic effects, small interfering RNA (siRNA) co-delivery, multimodality therapies, and oral delivery of therapeutics at disease sites. Liposomes with diverse range of modifications are being designed to generate improvised medicine delivery systems. Immuno-liposomes, linked with antibodies are promising tools for targeted drug delivery to specific cancer cells. In the recent times several anti-cancer agents in nanodelivery systems are under preclinical and clinical studies. Lipid-based liposomal delivery systems of self-amplifying RNA vaccines are showing promising effects.Globally research is being carried out in generating liposomes with higher compatibility within the biological system in targeting a wide array of diseases including cancer, overcoming multidrug resistance, inflammatory diseases, thrombosis, psoriasis, muscular dystrophy, spinal cord injury, neurologic diseases, diabetes, parasite induced diseases, and cardiovascular diseases.

show abstract

“…Surface-functionalized liposomes with antibodies decreased steric hindrance during targeting, facilitating binding of liposomes to cancer cells. 51 Anti-EphA10 is expressed in all subsets of breast cancer but is not expressed in normal breast tissue. 52 Nagano et al 53 revealed that the administration of an anti-EphA10 antibody significantly suppressed tumor growth in a xenograft mouse model, indicating anti-EphA10 as the target for breast cancer.…”

Section: In Vitro Cellular Uptake Of Epslrmentioning

confidence: 99%

Anti-EphA10 antibody-conjugated pH-sensitive liposomes for specific intracellular delivery of siRNA

Zang¹,

Ding²,

Zhao³

et al. 2016

IJN

View full text Add to dashboard Cite

Therapeutic delivery of small interfering RNA (siRNA) is a major challenge that limits its potential clinical application. Here, a pH-sensitive cholesterol–Schiff base–polyethylene glycol (Chol–SIB–PEG)-modified cationic liposome–siRNA complex, conjugated with the recombinant humanized anti-EphA10 antibody (Eph), was developed as an efficient nonviral siRNA delivery system. Chol–SIB–PEG was successfully synthesized and confirmed with FTIR and 1 H-NMR. An Eph–PEG–SIB–Chol-modified liposome–siRNA complex (EPSLR) was prepared and characterized by size, zeta potential, gel retardation, and encapsulation efficiency. Electrophoresis results showed that EPSLR was resistant to heparin replacement and protected siRNA from fetal bovine serum digestion. EPSLR exhibited only minor cytotoxicity in MCF-7/ADR cells. The results of flow cytometry and confocal laser scanning microscopy suggested that EPSLR enhanced siRNA transfection in MCF-7/ADR cells. Intracellular distribution experiment revealed that EPSLR could escape from the endo-lysosomal organelle and release siRNA into cytoplasm at 4 hours posttransfection. Western blot experiment demonstrated that EPSLR was able to significantly reduce the levels of MDR1 protein in MCF-7/ADR cells. The in vivo study of DIR-labeled complexes in mice bearing MCF-7/ADR tumor indicated that EPSLR could reach the tumor site rather than other organs more effectively. All these results demonstrate that EPSLR has much potential for effective siRNA delivery and may facilitate its therapeutic application.

show abstract

Etoposide-loaded immunoliposomes as active targeting agents for GD2-positive malignancies

Cited by 37 publications

References 44 publications

GD2‐targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma

GD2‐targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma

Multidynamic Liposomes in Nanomedicine: Technology, Biology, Applications, and Disease Targeting

Anti-EphA10 antibody-conjugated pH-sensitive liposomes for specific intracellular delivery of siRNA

Contact Info

Product

Resources

About